Fresenius Medical Care AG – Consensus indicates upside potential of 11.8%


Fresenius Medical Care AG found using the (FMS) ticker now have 4 analysts covering the stock with the consensus suggesting a ‘Hold’ rating. The target price ranges between 35.72 and 30.92 and has an average objective at 33.4. Together with the stock’s previous close at 29.87, this now indicates that there is upside potential of 11.8%. The 50 day moving average is at 32.16 and the 200 moving average now moves to 33.65. The market cap of the company is $17,646 million. You can visit the Company’s website by visiting:

The potential market capitalization would be $19,732 million based on market consensus.

You can now share it on Stocktwits, just click on the logo below and add the ticker in the text to be seen.

Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America and abroad. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; equipment, training and patient support services including clinical monitoring, assisting with follow-up and arranging delivery of supplies to the patient’s home; and contracted dialysis services with hospitals in the United States for hospitalized patients with end-stage renal disease (ESRD) and for patients with acute renal failure. The company also develops, manufactures and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granules, bloodlines, kidney pharmaceuticals and water treatment systems; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires and licenses renal pharmaceuticals; provides kidney medications and supplies to patients at home or in dialysis clinics; and provides vascular, cardiovascular and endovascular specialty services, an outpatient vascular surgery center, and nephrology and cardiology medical services. The company sells its products directly to dialysis clinics, hospitals and specialty treatment clinics, as well as through local sales forces, independent distributors, resellers and sales agents. As of February 23, 2022, it operated 4,171 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.


Comments are closed.